ChromaTan has won a $2.5 million FDA contract toward process development, design, and testing of an integrated, continuous downstream purification platform for production of monoclonal antibodies
Sponsored Content Brought to you by Collaboration with a contract development and manufacturing organization (CDMO) can make it possible to bring your drug to market — and to patients — faster, as additional resources allow...
Biologic monoclonal antibody (mAb) drugs are not just more targeted than small-molecule drugs, they are also larger, more complicated, and more variable. Consequently, biologic mAb drugs, which generate sizable revenues, may enjoy some degree...
Passage Bio, a developer of gene therapies for rare monogenic CNS diseases launched five months ago, will partner with Catalent’s Paragon Gene Therapy unit to develop a dedicated manufacturing suite at Paragon’s Harmans, MD, facility.
In this MilliporeSigma sponsored content, we explores they'r mini-pool approach as fast track process for small biotechs who are on a very challenging timeline. It enables us to start process development and production of early material before cell line development is completed.
Firm is looking for alternative platform to CEF manufacture for clinical-stage cancer and infectious disease vaccines.
MilliporeSigma signed a research agreement with the International Vaccine Institute (IVI) to help develop more scalable vaccine manufacturing processes
Quanterix plans to launch an IPO of at least $64 million, with proceeds set in part toward expanding commercial operations and supporting the planned rollout next year of its new Quanterix SR-X Ultra-Sensitive Biomarker Detection System™
A therapeutic protein or monoclonal antibody (mAb) can be turned into an effective therapy and a revenue-generating product only if it can be efficiently filtered from the process stream. If a product is inefficiently...
When new technologies are deployed, there’s always a fly in the ointment. In the case of single-use technology, extractables and leachables must be swatted away.
Please wait while you are redirected to the right page...